Peter Olson, Goonengerry
Aspirin be may relevant for people getting Alzheimer’s disease (AD) (Letters April 3).
In the peer reviewed medical journal Neuro Report, it states: the neurotoxic ‘actions of the Alzheimer peptide amyloid-B (AB) are dependent on its aggregation and B-sheet conformation’ and that in a test tube, Aspirin ‘inhibits human AB aggregation… reverses the B-sheet conformation’ and ‘Aspirin prevented enhanced AB aggregation by aluminum’. They state, Aspirin has been proven to ‘decrease the risk of developing Alzheimer’s disease by unknown mechanisms’.
Aspirin improves memory spatial learning in elderly rats but not in young rats.
A quote from a study of 702 Swedish people with a mean age of 83.9 years: ‘Users of high-dose aspirin had significantly lower prevalence of Alzheimer’s dementia and better-maintained cognitive function than non-users’. There were similar but not significant associations with use of low-dose aspirin.
Finally a study of 70 dementia patients found that 325mg of Aspirin daily … ‘appears to improve or stabilise declines in cerebral perfusion and cognition among patients with dementia’.
Other studies found vitamin B12 and B9 (Folate) were low in people with Alzheimer’s.